IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0219690.html
   My bibliography  Save this article

The impact of the single exit price policy on a basket of generic medicines in South Africa, using a time series analysis from 1999 to 2014

Author

Listed:
  • Rajatheran Moodley
  • Fatima Suleman

Abstract

Background: Regulating pharmaceutical markets have become a key strategy by most governments in ensuring the availability and accessibility of quality medicines to its citizens. The South African government, when faced with high medicine prices, implemented the Single Exit Price (SEP) in 2004. This study assessed the impact of the of the Single Exit Price (SEP) regulation introduced in South Africa in 2004 on a basket of generic. Method: Private sector price data of a basket of medicines (December 1999 to December 2014) was obtained from various price files (Pharmacy Software Vendors and Community Pharmacy). The price of the medicine was expressed in a single unit dose. The medicines investigated used the WHO/HAI methodology. The Interrupted Time-Series (ITS) model was used to estimate the change in slope and level of medicines investigated (50 originator and its available generics) before and after the policy change. Results: Majority of the medicines analysed reflect a substantial decrease in medicine prices immediately after implementation of the pricing regulations as reflected in both the change in level and the change in slope using the interrupted time series analysis. Discussion: This study indicates that the SEP regulation had an impact on medicine pricing in South Africa in both the short (immediately on the introduction) and long term (over the study period). Most medicines investigated showed a smaller yearly increase in price compared to before regulations. Conclusion: This study provides evidence of the impact of medicine pricing intervention from a middle–income country, and useful lessons can be drawn by other developing countries looking at introducing medicine price controls.

Suggested Citation

  • Rajatheran Moodley & Fatima Suleman, 2019. "The impact of the single exit price policy on a basket of generic medicines in South Africa, using a time series analysis from 1999 to 2014," PLOS ONE, Public Library of Science, vol. 14(7), pages 1-18, July.
    • Handle: RePEc:plo:pone00:0219690
    DOI: 10.1371/journal.pone.0219690
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0219690
    Download Restriction: no
    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0219690&type=printable
    Download Restriction: no
    File URL: https://libkey.io/10.1371/journal.pone.0219690?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Giuseppe Carone & Christoph Schwierz & Ana Xavier, 2012. "Cost-containment policies in public pharmaceutical spending in the EU," European Economy - Economic Papers 2008 - 2015 461, Directorate General Economic and Financial Affairs (DG ECFIN), European Commission.
    2. Danzon, Patricia M & Chao, Li-Wei, 2000. "Does Regulation Drive out Competition in Pharmaceutical Markets?," Journal of Law and Economics, University of Chicago Press, vol. 43(2), pages 311-357, October.
    3. Fernando Antoñanzas & Robert Terkola & Paul M. Overton & Natalie Shalet & Maarten Postma, 2017. "Defining and Measuring the Affordability of New Medicines: A Systematic Review," PharmacoEconomics, Springer, vol. 35(8), pages 777-791, August.
    4. Iván Moreno-Torres & Jaume Puig-Junoy & Josep Raya, 2011. "The impact of repeated cost containment policies on pharmaceutical expenditure: experience in Spain," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 12(6), pages 563-573, December.
    5. Christine de la Maisonneuve & Joaquim Oliveira Martins, 2013. "Public Spending on Health and Long-term Care: A new set of projections," OECD Economic Policy Papers 6, OECD Publishing.
    6. Rexford Santerre & John A. Vernon, 2005. "Assessing Consumer Gains from a Drug Price Control Policy in the U.S," NBER Working Papers 11139, National Bureau of Economic Research, Inc.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Katrina Perehudoff & Ivan Demchenko & Nikita V. Alexandrov & David Brutsaert & Angela Ackon & Carlos E. Durán & Faris El-Dahiyat & Firdaus Hafidz & Rezwan Haque & Rabia Hussain & Roderick Salenga & Fa, 2020. "Essential Medicines in Universal Health Coverage: A Scoping Review of Public Health Law Interventions and How They Are Measured in Five Middle-Income Countries," IJERPH, MDPI, vol. 17(24), pages 1-30, December.
    2. Joosse, Iris R. & Tordrup, David & Glanville, Julie & Kotas, Eleanor & Mantel-Teeuwisse, Aukje K. & van den Ham, Hendrika A., 2023. "Evidence on the effectiveness of policies promoting price transparency - A systematic review," Health Policy, Elsevier, vol. 134(C).
    3. Joosse, Iris R. & Tordrup, David & Bero, Lisa & Mantel-Teeuwisse, Aukje K. & van den Ham, Hendrika A., 2023. "A critical review of methodologies used in pharmaceutical pricing policy analyses," Health Policy, Elsevier, vol. 134(C).

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Brekke, Kurt R. & Holmås, Tor Helge & Straume, Odd Rune, 2015. "Price regulation and parallel imports of pharmaceuticals," Journal of Public Economics, Elsevier, vol. 129(C), pages 92-105.
    2. Martin Kenneally & Brenda Lynch, 2018. "Ageing, health status and coverage rate effects on community prescription costs in Ireland," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(5), pages 687-695, June.
    3. Ito, Yuki & Hara, Konan & Kobayashi, Yasuki, 2020. "The effect of inertia on brand-name versus generic drug choices," Journal of Economic Behavior & Organization, Elsevier, vol. 172(C), pages 364-379.
    4. repec:nip:nipewp:06/2015 is not listed on IDEAS
    5. Kurt R. Brekke & Chiara Canta & Odd Rune StraumeAuthor-Email: o.r.straume@eeg.uminho.p, 2015. "Does Reference Pricing Drive Out Generic Competition in Pharmaceutical Markets? Evidence from a Policy Reform," NIPE Working Papers 6/2015, NIPE - Universidade do Minho.
    6. Jaume Puig-Junoy & Santiago Rodríguez-Feijoó & Beatriz Lopez-Valcarcel, 2014. "Paying for Formerly Free Medicines in Spain After 1 Year of Co-Payment: Changes in the Number of Dispensed Prescriptions," Applied Health Economics and Health Policy, Springer, vol. 12(3), pages 279-287, June.
    7. Hanna Koskinen & Elina Ahola & Leena Saastamoinen & Hennamari Mikkola & Jaana Martikainen, 2014. "The impact of reference pricing and extension of generic substitution on the daily cost of antipsychotic medication in Finland," Health Economics Review, Springer, vol. 4(1), pages 1-10, December.
    8. Rachev, Boris & Uyei, Jennifer & Singh, Rajpal & Kowal, Stacey & Johnson, C. Erwin, 2021. "Stakeholder point of view on prescription drug affordability - a systematic literature review and content analysis," Health Policy, Elsevier, vol. 125(9), pages 1158-1165.
    9. Kwon, Hye-Young & Bae, Seungjin & Choi, Sang-eun & Park, Sylvia & Lee, Eui-Kyung & Park, Sungmin & Kim, Jinhyun, 2019. "Easy cuts, easy rebound: Drug expenditures with massive price cuts in Korea," Health Policy, Elsevier, vol. 123(4), pages 388-392.
    10. Randall S. Jones & Haruki Seitani, 2019. "Meeting fiscal challenges in Japan’s rapidly ageing society," OECD Economics Department Working Papers 1569, OECD Publishing.
    11. Birg, Laura, 2019. "Parallel imports and manufacturer rebates: Evidence from Germany," University of Göttingen Working Papers in Economics 363, University of Goettingen, Department of Economics.
    12. Nishida, Mitsukuni & Gil, Ricard, 2014. "Regulation, enforcement, and entry: Evidence from the Spanish local TV industry," International Journal of Industrial Organization, Elsevier, vol. 32(C), pages 11-23.
    13. Bergman , Mats A. & Granlund, David & Rudholm, Niklas, 2016. "Squeezing the last drop out of your suppliers: an empirical study of market-based purchasing policies for generic pharmaceuticals," Umeå Economic Studies 921, Umeå University, Department of Economics.
    14. Hostenkamp, Gisela, 2013. "Do follow-on therapeutic substitutes induce price competition between hospital medicines? Evidence from the Danish hospital sector," Health Policy, Elsevier, vol. 111(1), pages 68-77.
    15. Armel Ngami & Thomas Seegmuller, 2021. "Pollution and growth: The role of pension in the efficiency of health and environmental policies," International Journal of Economic Theory, The International Society for Economic Theory, vol. 17(4), pages 390-415, December.
    16. Bate, Roger & Jin, Ginger Zhe & Mathur, Aparna, 2011. "Does price reveal poor-quality drugs? Evidence from 17 countries," Journal of Health Economics, Elsevier, vol. 30(6), pages 1150-1163.
    17. Begoña Garcia Mariñoso & Izabela Jelovac & Pau Olivella, 2011. "External referencing and pharmaceutical price negotiation," Health Economics, John Wiley & Sons, Ltd., vol. 20(6), pages 737-756, June.
    18. Varsha Bangalee & Fatima Suleman, 2018. "An Overview of Medicine Pricing Policies that May be Applicable to Low-and Middle-Income Countries," Global Journal of Pharmacy & Pharmaceutical Sciences, Juniper Publishers Inc., vol. 6(4), pages 93-96, October.
    19. Vincenzo Atella & Jay Bhattacharya & Lorenzo Carbonari, 2008. "Pharmaceutical Industry, Drug Quality and Regulation: Evidence from US and Italy," NBER Working Papers 14567, National Bureau of Economic Research, Inc.
    20. Patricia M. Danzon & Y. Richard Wang & Liang Wang, 2005. "The impact of price regulation on the launch delay of new drugs—evidence from twenty‐five major markets in the 1990s," Health Economics, John Wiley & Sons, Ltd., vol. 14(3), pages 269-292, March.
    21. Nathalie Fombaron & Carine Milcent, 2007. "The distortionary effect of health insurance on health demand," Working Papers halshs-00587713, HAL.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0219690. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.